CAMBRIDGE, Mass.--(BUSINESS WIRE)--Food Allergy Science Initiative (FASI), a leading food allergy science nonprofit, is pleased to announce the promotion of Dr. Carlos Bosques, PhD to Chief Executive Officer of FASI effective today. Dr. Bosques’ extensive scientific leadership, interdisciplinary experience, and proven track-record as a drug developer make him the ideal leader to guide FASI in its next era of strategic impact..

马萨诸塞州剑桥市-食品过敏科学倡议（FASI）是一家领先的食品过敏科学非营利组织，很高兴地宣布将博士Carlos Bosques博士晋升为今天生效的FASI首席执行官。博士具有广泛的科学领导力，跨学科经验以及作为药物开发者的可靠记录，使他成为指导FASI在下一个战略影响时代的理想领导者。。

Dr. Bosques joined FASI in 2022 as Senior Vice President of Research and quickly became an integral part of the organization's leadership structure. Under Dr. Bosques’ leadership, FASI has released a Strategic Research Plan that continues to build foundational science that advances a deeper understanding of the biology of food allergies while launching translational research and drug discovery activities in collaboration with FASI’s scientific network.

Bosques博士于2022年加入FASI担任研究高级副总裁，并迅速成为该组织领导结构的组成部分。在Bosques博士的领导下，FASI发布了一项战略研究计划，继续建立基础科学，加深对食物过敏生物学的理解，同时与FASI的科学网络合作开展转化研究和药物发现活动。

As CEO, Dr. Bosques will build and steward relationships with FASI’s generous donors and its broader community..

作为首席执行官，博斯克斯博士将与FASI的慷慨捐助者及其更广泛的社区建立和管理关系。。

A biological chemist and bioengineer, Dr. Bosques brings with him a wealth of leadership experience including over 17 years in developing biomedical technology platforms and novel therapeutics. His experience in identifying therapeutic business opportunities and developing immuno-therapeutics from discovery to the clinical stage represents a great asset for the next phase of FASI.

Bosques博士是生物化学家和生物工程师，他带来了丰富的领导经验，包括17年来开发生物医学技术平台和新型治疗药物。他在确定治疗性商业机会和开发从发现到临床阶段的免疫治疗方面的经验代表了FASI下一阶段的巨大资产。

He has authored numerous publications and holds patents in the fields of immunology, glycobiology and biotherapeutics..

他撰写了大量出版物，并在免疫学，糖生物学和生物治疗学领域拥有专利。。

“We are confident that under Carlos’s visionary leadership, FASI is poised for unparalleled growth and innovation. His proven track-record and deep industry knowledge aligns perfectly with our organizational goals. Carlos has already proven himself as a leader in FASI,” said Christine Olsen, MD, Executive Chair, FASI..

“我们相信，在卡洛斯有远见的领导下，FASI为无与伦比的增长和创新做好准备，他久经考验的业绩和深刻的行业知识与我们的组织目标完全一致，卡洛斯已经证明自己是FASI的领导者，”克里斯蒂娜·奥尔森博士，FASI执行主席。。

As CEO, Dr. Bosques will lead FASI's continued efforts to drive scientific innovation and raise awareness for individuals living with food allergies and their families.

作为首席执行官，博斯克斯博士将领导FASI继续努力推动科学创新，提高对食物过敏患者及其家属的认识。

'I’m deeply honored to step into the role of FASI's CEO, and lead the team in passionately pursuing our remarkable mission,' said Dr. Bosques.' Food allergies impact millions of people worldwide and unfortunately there are very limited treatment options. I’m committed to driving forward our mission of advancing scientific knowledge, finding innovative solutions, and providing hope and relief to patients and families affected by food allergies.'.

博斯克斯博士说：“我非常荣幸地担任FASI首席执行官的角色，并领导团队积极追求我们卓越的使命。”食物过敏影响全世界数百万人，不幸的是治疗方案非常有限。我致力于推动我们推进科学知识的使命，寻找创新的解决方案，为受食物过敏影响的患者和家属提供希望和救济。

Since 2016, FASI has invested $37+ million in breakthrough food allergy science in collaboration with a network of 100+ scientists. https://foodallergyscience.org.

自2016年以来，FASI与100多名科学家网络合作，在突破性食品过敏科学方面投入了370多万美元。https://foodallergyscience.org.